Network Meta-Analysis Ranks 21 Antidepressants for Acute Depression
This landmark network meta-analysis provides the largest comparative efficacy and tolerability ranking of antidepressants available, informing evidence-based agent selection for acute major depressive disorder.
Antidepressants show varied efficacy and acceptability for major depressive disorder.
This study reviews the comparative efficacy and acceptability of 21 antidepressants for treating major depressive disorder in adults, helping guide evidence-based treatment decisions. All antidepressants were more effective than placebo; agomelatine and fluoxetine showed higher acceptability with fewer discontinuations. The findings highlight differences in efficacy and acceptability among antidepressants, providing valuable insights for prescribing decisions in major depressive disorder. Antidepressants vary significantly in efficacy and acceptability, informing personalized treatment in major depressive disorder.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR
Citation:Cipriani A, Furukawa TA, Salanti G, et al. Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. Focus (American Psychiatric Publishing). 2026;24(2):252-262. doi:10.1176/appi.focus.26024115